Payment overview · 2025
General Payments
$10,301.10
101 reported records · 24 companies
Healthcare provider profile · identity verified
Yanfeng Chen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1740280171
Verified facts
What the public records show
CMS Open Payments records show Yanfeng Chen, M.D. received $10,301.10 in general payments during 2025 across 101 reported records.
Gilead Sciences, Inc. accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Farxiga, Jardiance, Kerendia, Linzess, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $5,252.42 | 51.0% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,018.75 | 9.9% | 19 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $691.74 | 6.7% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $547.05 | 5.3% | 7 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $381.64 | 3.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $375.00 | 3.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $364.67 | 3.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $297.69 | 2.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $236.48 | 2.3% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $147.73 | 1.4% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $141.62 | 1.4% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.00 | 1.2% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $125.00 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $125.00 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $124.76 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $98.63 | 1.0% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.53 | 0.5% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $42.74 | 0.4% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $30.00 | 0.3% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $26.67 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.00 | 0.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.71 | 0.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $23.53 | 0.2% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $19.74 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,423.72 | 97 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,860.00 | 3 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $381.64 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $375.00 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $374.97 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $372.31 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $299.83 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $297.69 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $271.47 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $236.48 | 6 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $153.57 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $147.73 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $124.76 | 1 | 2025 |
Source payment records
|
|||||
| Otezla Normalized: otezla |
Drug | Amgen Inc. | $122.22 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $98.63 | 6 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $75.06 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $66.56 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $64.67 | 3 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $42.74 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.17 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.60 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 25 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 40 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 285 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 253 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 83 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 36 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
285 | 72 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
253 | 53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 29 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
133 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1218 | 348 |
| Amlodipine Besylate | Amlodipine Besylate | 1154 | 335 |
| Losartan Potassium | Losartan Potassium | 1085 | 288 |
| Vascepa | Icosapent Ethyl | 865 | 211 |
| Meloxicam | Meloxicam | 652 | 333 |
| Donepezil Hcl | Donepezil Hcl | 623 | 163 |
| Metformin Hcl | Metformin Hcl | 557 | 151 |
| Tamsulosin Hcl | Tamsulosin Hcl | 544 | 135 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 442 | 146 |
| Ibuprofen | Ibuprofen | 416 | 312 |
| Simvastatin | Simvastatin | 386 | 122 |
| Finasteride | Finasteride | 382 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 380 | 120 |
| Omeprazole | Omeprazole | 361 | 167 |
| Meclizine Hcl | Meclizine Hcl | 359 | 176 |
| Raloxifene Hcl | Raloxifene Hcl | 309 | 79 |
| Trazodone Hcl | Trazodone Hcl | 308 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 77 |
| Halobetasol Propionate | Halobetasol Propionate | 300 | 134 |
| Azithromycin | Azithromycin | 289 | 242 |
| Farxiga | Dapagliflozin Propanediol | 285 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 283 | 115 |
| Glipizide Er | Glipizide | 278 | 73 |
| Jardiance | Empagliflozin | 253 | 53 |
| Folic Acid | Folic Acid | 238 | 64 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 212 | 74 |
| Ammonium Lactate | Ammonium Lactate | 200 | 84 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 171 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 72 |
| Atenolol | Atenolol | 160 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 157 | 49 |
| Gabapentin | Gabapentin | 154 | 54 |
| Diclofenac Epolamine | Diclofenac Epolamine | 149 | 77 |
| Pioglitazone Hcl | Pioglitazone Hcl | 148 | 42 |
| Allopurinol | Allopurinol | 146 | 37 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 144 | 57 |
| Januvia | Sitagliptin Phosphate | 142 | 37 |
| Lisinopril | Lisinopril | 139 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 133 | 51 |
| Vemlidy | Tenofovir Alafenamide | 133 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 132 | 67 |
| Montelukast Sodium | Montelukast Sodium | 129 | 45 |
| Alendronate Sodium | Alendronate Sodium | 128 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 34 |
| Mirtazapine | Mirtazapine | 123 | 38 |
| Hydrocortisone | Hydrocortisone | 118 | 46 |
| Eliquis | Apixaban | 115 | 29 |
| Mupirocin | Mupirocin | 111 | 60 |
| Rybelsus | Semaglutide | 110 | 24 |
| Synthroid | Levothyroxine Sodium | 110 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 102 | 32 |
| Metformin Hcl Er | Metformin Hcl | 101 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 94 | 43 |
| Colchicine | Colchicine | 83 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 44 |
| Linzess | Linaclotide | 83 | 24 |
| Xarelto | Rivaroxaban | 82 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 25 |
| Icosapent Ethyl | Icosapent Ethyl | 75 | 31 |
| Baclofen | Baclofen | 73 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 67 | 22 |
| Amoxicillin | Amoxicillin | 66 | 63 |
| Azelastine Hcl | Azelastine Hcl | 65 | 31 |
| Carvedilol | Carvedilol | 61 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 61 | 29 |
| Methimazole | Methimazole | 60 | suppressed |
| Procto-Med Hc | Hydrocortisone | 60 | 16 |
| Celecoxib | Celecoxib | 59 | 19 |
| Famotidine | Famotidine | 59 | 28 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 59 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 58 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | suppressed |
| Tradjenta | Linagliptin | 57 | 12 |
| Memantine Hcl | Memantine Hcl | 56 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 55 | 15 |
| Furosemide | Furosemide | 54 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 21 |
| Loperamide | Loperamide Hcl | 48 | 39 |
| Jentadueto | Linagliptin/Metformin Hcl | 47 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 46 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Clotrimazole | Clotrimazole | 42 | 12 |
| Prednisone | Prednisone | 42 | 21 |
| Roflumilast | Roflumilast | 42 | suppressed |
| Creon | Lipase/Protease/Amylase | 40 | 15 |
| Potassium Chloride | Potassium Chloride | 40 | 15 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 23 |
| Valsartan | Valsartan | 36 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 13 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 33 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | 16 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 29 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Lidocaine | Lidocaine | 29 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 24 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Proctozone-Hc | Hydrocortisone | 25 | suppressed |
| Fluocinonide | Fluocinonide | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 23 | 11 |
| Mometasone Furoate | Mometasone Furoate | 23 | 11 |
| Silodosin | Silodosin | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 22 | suppressed |
| Acarbose | Acarbose | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Glipizide Xl | Glipizide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Entecavir | Entecavir | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Mitigare | Colchicine | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Prolia | Denosumab | 17 | 16 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Multaq | Dronedarone Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 15 | 13 |
| Trulicity | Dulaglutide | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,301.10 · 101 records | Gilead Sciences, Inc. | AIRSUPRA, AREXVY, Arikayce, BREZTRI, BRUKINSA, Brinsupri, CAMZYOS, CAPVAXIVE, COLLAGENASE SANTYL, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Fluad, Flucelvax, GARDASIL 9, IBSRELA, ImmunoCAP, JARDIANCE, Kerendia, LINZESS, Livdelzi, Otezla, Ozempic, PENMENVY, REPATHA, REZDIFFRA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VOWST, VYALEV, Vest Therapy Und, Wegovy, XIFAXAN, ZENPEP, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error